Our unique platform encompasses all aspects of drug discovery and pre-clinical development, enabling us to discover novel therapies for challenging or currently undruggable targets. We start our drug discovery process with bioinformatic analysis of the target RNA, providing us with sufficient information to select and synthesize relevant ASO drug candidates. These are then tested in our labs for efficacy and potency of target knockdown as well as safety aspects in relevant cell lines or primary cells. Candidates with promising activity and a favorable safety profile are further investigated for therapeutic activity in vitro and progress to in vivo tolerability testing and subsequent investigation of therapeutic activity in in vivo disease models.
We pair our convincing technical capabilities with strong expertise and a global network: Secarna works with a team of experts in the field of antisense drug discovery and development, an international network of highly recognized KOLs as well as a validated partnership model.
Oligofyer™ allows us to fully screen all relevant databases for every possible n-mer ASOs per target. ASOs with a potential for sequence-dependent off-target effects and sequences having potentially toxic sequence motifs will be eliminated, cross reactivity with other species – if required – is also considered.
With Oligofyer™, we filter for ASOs with strongly enhanced probability for efficacy and rationally design ASO molecules with an exceptionally high hit rate.
The bioinformatic system directs selection of typically 100 to 500 molecules per target entering in vitro screens in relevant cell systems.
Since its inception, Secarna has become a global leader in discovering and developing 3rd generation ASOs – a technology also validated, as identical chemistry is employed by Santaris/Roche.
Secarna minimizes the potential of ASO therapy-related complexities (e.g. unintended immune system responses, liver and kidney toxicities) by using the company’s own focused molecule design and selection strategies as well as customized development solutions to address the aforementioned matters and generate ASO candidates meeting the highest safety and efficacy requirements.
Our LNAplus™-based ASOs are characterized by excellent stability and target affinity. Employing state-of-the-art chemistry, we achieve a circa 10-fold increased potency compared to preceding generations of ASOs.
Furthermore, our antisense oligonucleotides do not require conjugation, transfection or delivery reagents to exert their in vitro and in vivo activity in various cell types, tissues and organs. IC50 values of Secarna’s molecules are routinely in the nanomolar range without the support of delivery systems.
Consequently, our molecule’s therapeutic window is expected to be greatly wider when compared to preceding generations of ASOs and alternative modalities.
Our state-of-the-art high throughput platform has been validated by in-house projects and in partnerships with academic and industry collaborators. It has successfully proven to be fast, reliable, scalable, efficient and provides for a uniquely integrated workflow